1772
Z. Li et al. / Bioorg. Med. Chem. Lett. 15 (2005) 1769–1772
Lett. 2004, 45, 1247–1251; (m) Xu, Y.; Qian, X., et al.
Bioorg. Med. Chem. 2003, 11, 5427–5433.
In summary, a new family of 2-aminothiazonaphthal-
imides as visible light activatable photonucleases was
synthesized and determined to have different DNA
photocleaving activities. The order of their photocleav-
ing abilities was parallel to that of their intercalative
properties. The compound with linear heterocyclic-fused
chromophore exhibited higher DNA intercalating and
DNA photocleaving activities than the one with angular
chromophore. B2 showed the highest activity. Mecha-
nism experiment showed that superoxide anion was
involved.
4. (a) Bran˜a, M. F.; Ramos, A. Curr. Med. Chem.: Anticancer
Agents 2001, 1, 237–255; (b) Bran˜a, M. F.; Cacho, M.;
Garcia, M. A., et al. J. Med. Chem. 2002, 45, 5813–5816;
(c) Sami, S. M.; Dorr, R. T.; Alberts, D. S.; Iyengar, B. S.;
Remers, W. A. J. Med. Chem. 1996, 39, 4978–4987; (d)
Sami, S. M.; Dorr, R. T.; Alberts, D. S.; Solyom, A. M.;
Remers, W. A. J. Med. Chem. 2000, 43, 3067–3073.
5. (a) Zhang, A.; Xiong, W.; Hilbert, J. E.; DeVita, E. K.;
Bidlack, J. M.; Neumeyer, J. L. J. Med. Chem. 2004, 47,
1886–1888; (b) van Vliet, L. A.; Rodenhuis, N.; Wikstrom,
H.; Pugsley, T. A.; Serpa, K. A., et al. J. Med. Chem. 2000,
43, 3549–3557.
6. (a) Malviya, V. K.; Liu, P. Y.; Alberts, D. S.; Surwit, E. A.;
Craig, J. B.; Hanningan, E. V. Am. J. Clin. Oncol. 1992, 15,
41–44; (b) Rosell, R.; Carles, J.; Abad, A.; Ribelles, N.;
Barnadas, A.; Benavides, A.; Martin, M. Invest. New Drugs
1992, 10, 171–175.
Acknowledgments
Financial support by the National Key Project for Basic
Research (2003CB114400) and under the auspices of
National Natural Science Foundation of China is
greatly appreciated.
7. Zhang, A.; van Vliet, S., et al. Tetrahedron Lett. 2003, 44,
6459–6462.
8. Compound A1: mp >300 ꢁC. 1H NMR (DMSO-d6) d
(ppm): 2.64 (s, 6H, NCH3), 3.10 (s, 2H, NCH2), 4.32 (t,
J1 = 6.0 Hz, J2 = 6.0 Hz, 2H, CONCH2), 7.85 (t,
J1 = 7.8 Hz, J2 = 7.8 Hz, 1H, 2-H), 8.48 (t, J = 7.6 Hz,
3H, 1-H, NH2), 8.72 (d, J = 8 Hz, 1H, 3-H), 8.87 (s, 1H, 7-
H). HRMS: calcd for C17H17N4O2S (M+H)+: 341.1072.
Found: 341.1070. IR (KBr): 2927, 2857, 1730, 1646, 1351,
779 cmÀ1. Compound A2: mp 260–261 ꢁC. 1H NMR
(DMSO-d6) d (ppm): 1.62 (s, 2H, CH2), 2.59 (s, 6H,
NCH3), 2.97 (s, 2H, NCH2), 4.11 (s, 2H, CONCH2), 7.84 (t,
J1 = 7.8 Hz, J2 = 7.8 Hz, 1H, 2-H), 8.46 (d, J = 7.8 Hz, 1H,
1-H), 8.50 (s, 2H, NH2), 8.73 (d, J = 8.4 Hz, 1H, 3-H), 8.85
(s, 1H, 7-H). HRMS: calcd for C18H19N4O2S (M+H)+:
355.1229. Found: 355.1211. IR (KBr): 2920, 2850, 1720,
1650, 1330, 779 cmÀ1. Compound B1: mp 290–291 ꢁC 1H
NMR (DMSO-d6) d (ppm): 2.50 (s, 6H, NCH3), 2.91 (s, 2H,
NCH2), 4.26 (s, 2H, CONCH2), 7.84 (t, J1 = 8 Hz,
J2 = 8 Hz, 1H, 2-H), 8.03 (s, 2H, NH2), 8.28 (d,
J = 8.2 Hz, 1-H), 8.36 (d, J = 6 Hz, 1H, 3-H), 8.40 (s, 1H,
10-H). HRMS: calcd for C17H17N4O2S (M+H)+: 341.1072.
Found: 341.1073. IR (KBr): 2921, 2850, 1696, 1654, 1330,
777 cmÀ1. Compound B2: mp 240–241 ꢁC. 1H NMR
(DMSO-d6) d (ppm): 1.82 (t, J1 = 6.4 Hz, J2 = 7.2 Hz, 2H,
CH2), 2.28 (s, 6H, NCH3), 3.16 (s, 2H, NCH2), 4.06 (t,
J1 = 7.2 Hz, J2 = 7.2 Hz, 2H, CONCH2, 7.79 (t,
J1 = 7.8 Hz, J2 = 8 Hz, 1H, 2-H), 8.01 (s, 2H, NH2), 8.20
(d, J = 8.4 Hz, 1-H), 8.31 (d, J = 7.2 Hz, 1H, 3-H), 8.34 (s,
1H, 10-H). HRMS: calcd for C18H19N4O2S (M+H+):
355.1229. Found: 355.1219. IR (KBr): 2960, 2823, 1695,
References and notes
1. (a) Parrish, J. A.; Fitzpatrick, T. B.; Tannenbaum, L.;
Pathak, M. A. N. Eng. J. Med. 1974, 291, 1207–1211; (b)
Jori, G.; Reddi, E. In Photodynamic Therapy of Neoplastic
Disease; Kessel, D., Ed.; CRC: Boston, 1990; pp 117–130;
(c) Henderson, B. W.; Dougherty, T. J. Photochem.
Photobiol. 1992, 55, 145–157.
2. (a) Cimino, D. G.; Gamper, H. B.; Isaacs, S. T.; Hearst, J.
E. Annu. Rev. Biochem. 1985, 54, 1151–1193; (b) Bailly, C.;
Mollegard, N. E.; Nielsen, P. E.; Waring, M. J. EMBO J.
1995, 9, 2121–2131; (c) Briener, K. M.; Daugherty, M. A.;
Oas, T. G.; Thorp, H. H. J. Am. Chem. Soc. 1995, 117,
11673–11679.
3. (a) Armitage, B. Chem. Rev. 1998, 98, 1171–1200; (b) Saito,
I.; Nakatani, K. Bull. Chem. Soc. Jpn. 1996, 69, 3007–3019;
(c) Satio, I.; Takayama, M.; Sakurai, T. J. Am. Chem. Soc.
1994, 116, 2653–2654; (d) Satio, I.; Takayama, M. J. Am.
Chem. Soc. 1995, 117, 5590–5591; (e) Satio, I.; Takayama,
M.; Sugiyama, H.; Nakatani, K. J. Am. Chem. Soc. 1995,
117, 6406–6407; (f) Qian, X.; Huang, T., et al. J. Chem.
Soc., Perkin Trans. 2 2000, 715–718; (g) Qian, X.; Yao, W.,
et al. Tetrahedron Lett. 2001, 42, 6175–6178; (h) Qian, X.;
Mao, P.; Yao, W.; Guo, X. Tetrahedron Lett. 2002, 43,
2995–2998; (i) Yao, W.; Qian, X.; Hu, Q. Tetrahedron Lett.
2000, 41, 7711–7715; (j) Li, Y.; Xu, Y.; Qian, X., et al.
Bioorg. Med. Chem. Lett. 2003, 13, 3513–3515; (k) Qian, X.;
Li, Y.; Xu, Y., et al. Bioorg. Med. Chem. Lett. 2004, 14,
2665–2668; (l) Li, Y.; Xu, Y.; Qian, X., et al. Tetrahedron
1651, 1335, 779 cmÀ1
9. Gupta, M.; Ali, R. J. Biochem. 1984, 95, 1253–1257.
.